Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
VOCABRIA + REKAMBYS RESOURCES
Resources
-
Expand to See More
2024 AIDS Abstract Booklet
A digital booklet containing three abstracts from AIDS 2024, focusing on the CARLOS, BEYOND and COMBINE-2 Studies.
PM-IE-CBR-BKLT-240001
SOLAR Digital Leaflet
A digital leave behind covering key highlights from the SOLAR head-to-head switch study.
PM-IE-CBR-LBND-230001
Vocabria + Rekambys Administration Poster
An administration poster for clinics or administration rooms with details on how to prepare and inject Vocabria + Rekambys.
PM-IE-CBR-PSTR-240001
Patient Resources
-
Expand to See More
Vocabria + Rekambys Patient Information Booklet
A printed booklet to provide practical information for patients post-prescription of Vocabria + Rekambys. This is to support patients to understand the treatment and ensure people living with HIV are aware of their role in treatment success.
NP-IE-CBR-LBND-230001
V&R Appointment Reminder Card
Appointment card for patients prescribed Vocabria + Rekambys
NP-IE-CBR-CRD-240001
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
REKAMBYS (rilpivirine long acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under licence by the ViiV Healthcare group of companies.
All other trademarks are owned by the ViiV Healthcare group, or its licensor.
©2024 GSK group of companies. All rights reserved.
Date of preparation: September 2024 | PM-IE-CBR-WCNT-240008
